<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606098</url>
  </required_header>
  <id_info>
    <org_study_id>CAIRO4</org_study_id>
    <nct_id>NCT01606098</nct_id>
  </id_info>
  <brief_title>The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer</brief_title>
  <acronym>CAIRO4</acronym>
  <official_title>The Role of Surgery of the Primary Tumour With Few or Absent Symptoms in Patients With Synchronous Unresectable Metastases of Colorectal Cancer, a Randomized Phase III Study. A Study of the Dutch Colorectal Cancer Group (DCCG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Colorectal Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dutch Colorectal Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical benefit of resection of the primary tumour in patients with synchronous&#xD;
      unresectable metastases is not known. In the literature studies usually describe&#xD;
      retrospective selected patients with synchronous metastases treated with or without resection&#xD;
      of the primary tumour. All these studies are biased in patient selection and there are no&#xD;
      prospective randomized studies on this topic. In patients with few or absent symptoms of the&#xD;
      primary tumour, arguments both in favour and against initial resection have been presented,&#xD;
      and therefore a randomized trial is warranted. Although recent publications suggest that&#xD;
      resection of the primary tumour in synchronous metastasized colon cancer patients might not&#xD;
      be necessary, this appears to be based on feasibility and not on clinical outcome. Several&#xD;
      studies comparing large groups of patients with or without resection of the primary tumour&#xD;
      suggest an improved survival when the primary tumour is resected. A potential benefit of&#xD;
      resection of the primary tumour is to prevent complications of the primary tumour during&#xD;
      chemotherapy treatment or during later stages of the disease. A recent analysis of the CAIRO&#xD;
      and CAIRO2 data showed that metastatic colon cancer patients who had a resection of the&#xD;
      primary tumour prior to study entry, had an improved survival compared to patients without a&#xD;
      resection of the primary tumour. However, these patients were selected after the primary&#xD;
      tumour was resected and therefore these results are not corrected for surgical morbidity and&#xD;
      mortality. The investigators here propose a randomized trial in order to demonstrate that&#xD;
      resection of the primary tumour does improve overall survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from randomisation until death, assessed up to 5 years</time_frame>
    <description>Overall survival of the intent-to-treat population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Time from randomisation until first progression or death whichever comes first, asessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to chemotherapy</measure>
    <time_frame>Fist-line chemotherapy, assessed until progression</time_frame>
    <description>Response rate according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic therapy related toxicity</measure>
    <time_frame>Every 3 weeks during first-line treatment</time_frame>
    <description>Adverse events grade 3-4 according to NCI-CTC 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery related morbidity and mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Every 6 months from randomisation until first progression</time_frame>
    <description>EORTC QLQ-C30 and CR38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interval between randomization and initiation of systemic treatment</measure>
    <time_frame>Number of days between randomization and initiation of systemic treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-benefit analyses</measure>
    <time_frame>Until end of first-line systemic treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients requiring resection of the primary tumour in the non-resection arm</measure>
    <time_frame>Time from randomisation until death, assessed up to 5 years</time_frame>
    <description>Number of patients requiring resection of the primary tumour in the non-resection arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in patients in whom treatment according to protocol was initiated</measure>
    <time_frame>Time form randomisation until death, assessed up to 5 years</time_frame>
    <description>Having received at least one cycle of systemic treatment in arm A and surgery in arm B</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Primary Tumour</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Systemic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First-line fluoropyrimidine-based chemotherapy with bevacizumab initiated within 4 weeks of randomization, followed by salvage therapy upon progression at the discretion of the local investigator. Surgery of primary tumour will be performed only when indicated by local signs or symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery followed by systemic treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgery within 4 weeks of randomization followed by fluoropyrimidine-based chemotherapy with bevacizumab until progression or unacceptable toxicity, followed by salvage therapy upon progression at the discretion of the local investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery of the primary tumour</intervention_name>
    <description>Surgical resection of the colon tumour</description>
    <arm_group_label>Surgery followed by systemic treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systemic treatment</intervention_name>
    <description>First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:&#xD;
5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)</description>
    <arm_group_label>Surgery followed by systemic treatment</arm_group_label>
    <arm_group_label>Systemic treatment</arm_group_label>
    <other_name>Bevacizumab in combination with fluoropyrimidine-based schedules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological proof of colorectal cancer&#xD;
&#xD;
          -  Resectable primary tumour in situ with unresectable distant metastases&#xD;
&#xD;
          -  No indication for neo-adjuvant (chemo)radiation&#xD;
&#xD;
          -  No severe signs or symptoms related to the primary tumour (i.e. severe bleeding,&#xD;
             obstruction, severe abdominal pain) that require immediate surgery or other&#xD;
             symptomatic treatment (e.g. stenting)&#xD;
&#xD;
          -  No prior systemic treatment for advanced disease&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Laboratory values obtained ≤ 4 weeks prior to randomization: Adequate bone marrow&#xD;
             function (Hb ≥ 6.0 mmol/L, absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 100 x&#xD;
             109/L), renal function (serum creatinine ≤ 1.5x ULN and creatinine clearance, Cockroft&#xD;
             formula, ≥ 30 ml/min), liver function (serum bilirubin ≤ 2 x ULN, serum transaminases&#xD;
             ≤ 3 x ULN without presence of liver metastases or ≤ 5x ULN with presence of liver&#xD;
             metastases)&#xD;
&#xD;
          -  Expected adequacy of follow-up&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  CT scan abdomen and CT thorax/X-thorax performed ≤ 4 weeks prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  Unresectable primary tumour (i.e. neurovascular encasement, substantial ingrowth in&#xD;
             pancreatic head), or any condition preventing the safety or feasibility of resection&#xD;
             of the primary tumour, i.e. massive ascites or extensive peritoneal disease&#xD;
&#xD;
          -  Requirement of neoadjuvant (chmo)radiation therapy&#xD;
&#xD;
          -  Second primary malignancy within the past 5 years with the exception of adequately&#xD;
             treated in situ carcinoma of any organ or basal cell carcinoma of the skin&#xD;
&#xD;
          -  Any medical condition that prevents the safe administration of systemic treatment&#xD;
&#xD;
          -  Previous intolerance of fluoropyrimidines, known dihydropyrimidine dehydrogenase (DPD)&#xD;
             deficiency&#xD;
&#xD;
          -  Planned radical resection of all metastatic disease&#xD;
&#xD;
          -  Uncontrolled hypertension, i.e. values consistently &gt; 150/100 mmHg&#xD;
&#xD;
          -  Use of ≥ 3 antihypertensive drugs&#xD;
&#xD;
          -  Significant cardiovascular disease &lt; 1 yr before randomization (symptomatic congestive&#xD;
             heart failure, myocardial infarction, unstable angina pectoris, serious uncontrolled&#xD;
             cardiac arrhythmia, cerebro vascular event)&#xD;
&#xD;
          -  Chronic active infection&#xD;
&#xD;
          -  Concurrent treatment with any other anti-cancer therapy as described per protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Koopman, Prof MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. JW de Wilt, Prof MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Aalborg</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospital Herning</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde hospital</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Amstelland</name>
      <address>
        <city>Amstelveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VUMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuis</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelmina Ziekenhuis</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Haaglanden en Bronovo Nebo</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slingeland Ziekenhuis</name>
      <address>
        <city>Doetinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Annaziekenhuis</name>
      <address>
        <city>Geldrop</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Jansdal</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkerliek Ziekenhuis</name>
      <address>
        <city>Helmond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <zip>6542 KN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterland Ziekenhuis</name>
      <address>
        <city>Purmerend</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurentius Ziekenhuis</name>
      <address>
        <city>Roermond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3007 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fransicus Gastuis &amp; Vlietland</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Rivierenland</name>
      <address>
        <city>Tiel</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Tweesteden</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernhoven Ziekenhuis</name>
      <address>
        <city>Uden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernhoven Ziekenhuis</name>
      <address>
        <city>Veghel</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaans Medisch Centrum</name>
      <address>
        <city>Zaandam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.dccg.nl</url>
    <description>Dutch Colorectal Cancer Group</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgery</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

